Wedbush Securities’s Aquestive Therapeutics AQST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$68K Buy
14,700
+200
+1% +$889 ﹤0.01% 1273
2026
Q2
$60K Buy
+14,500
New +$61K ﹤0.01% 1285
2021
Q3
– Sell
-10,500
Closed -$42K – 1171
2021
Q2
$42K Buy
10,500
+500
+5% +$2K ﹤0.01% 1150
2021
Q1
$52K Buy
+10,000
New +$53.2K ﹤0.01% 1063
2020
Q4
– Sell
-103,240
Closed -$501K – 873
2020
Q3
$501K Sell
103,240
-33,683
-25% -$220K 0.05% 429
2020
Q2
$665K Buy
136,923
+50,157
+58% +$231K 0.06% 322
2020
Q1
$190K Buy
86,766
+24,332
+39% +$92.4K 0.02% 700
2019
Q4
$363K Sell
62,434
-36,055
-37% -$188K 0.03% 595
2019
Q3
$313K Buy
98,489
+27,756
+39% +$104K 0.03% 621
2019
Q2
$297K Buy
+70,733
New +$362K 0.03% 631

Other funds holding AQST

Wedbush Securities's AQST Position: Q3 2026 in Review

Wedbush Securities increased its Aquestive Therapeutics (AQST) stake by 1.4% in Q3 2026, buying an estimated $889 and bringing the position to 14,700 shares worth $68K. The position accounts for ﹤0.01% of the portfolio, ranked #1273.

Wedbush Securities first reported a position in AQST in Q2 2019 and has held it in 10 quarters since. The position peaked at $665K in Q2 2020. 190 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

  • Wedbush Securities held 14,700 shares of Aquestive Therapeutics worth $68K as of Q3 2026.
  • Wedbush Securities bought 200 Aquestive Therapeutics shares in Q3 2026, an estimated $889.
  • Aquestive Therapeutics made up ﹤0.01% of Wedbush Securities's portfolio in Q3 2026, its #1273 holding.
  • Wedbush Securities first reported a position in Aquestive Therapeutics in Q2 2019 and has held it in 10 quarters since.
  • Wedbush Securities's Aquestive Therapeutics position peaked at $665K in Q2 2020.
  • 190 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Wedbush Securities's 13F filing for Q3 2026, filed 22 Oct 2026.